Arcutis Biotherapeutics Inc (ARQT) - Total Assets
Based on the latest financial reports, Arcutis Biotherapeutics Inc (ARQT) holds total assets worth $488.54 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Arcutis Biotherapeutics Inc - Total Assets Trend (2017–2025)
This chart illustrates how Arcutis Biotherapeutics Inc's total assets have evolved over time, based on quarterly financial data. Also see Arcutis Biotherapeutics Inc stock valuation for the company's overall valuation and market capitalisation.
Arcutis Biotherapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Arcutis Biotherapeutics Inc's total assets of $488.54 Million consist of 95.0% current assets and 5.0% non-current assets. Review ARQT total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 9.9% |
| Accounts Receivable | $146.23 Million | 33.8% |
| Inventory | $22.63 Million | 5.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $14.81 Million | 3.4% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Arcutis Biotherapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Arcutis Biotherapeutics Inc stock quote for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Arcutis Biotherapeutics Inc's current assets represent 95.0% of total assets in 2025, a decrease from 100.0% in 2017.
- Cash Position: Cash and equivalents constituted 9.9% of total assets in 2025, down from 89.5% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 33.8% of total assets.
Arcutis Biotherapeutics Inc Competitors by Total Assets
Key competitors of Arcutis Biotherapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Arcutis Biotherapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.92 | 3.20 | 20.03 |
| Quick Ratio | 2.67 | 3.04 | 20.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $307.33 Million | $228.84 Million | $362.71 Million |
Arcutis Biotherapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Arcutis Biotherapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 13.61 |
| Latest Market Cap to Assets Ratio | 6.82 |
| Asset Growth Rate (YoY) | 24.1% |
| Total Assets | $432.97 Million |
| Market Capitalization | $2.96 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Arcutis Biotherapeutics Inc's assets at a significant premium (6.82x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Arcutis Biotherapeutics Inc's assets grew by 24.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Arcutis Biotherapeutics Inc (2017–2025)
The table below shows the annual total assets of Arcutis Biotherapeutics Inc from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $432.97 Million | +24.10% |
| 2024-12-31 | $348.89 Million | +2.20% |
| 2023-12-31 | $341.37 Million | -24.02% |
| 2022-12-31 | $449.27 Million | +10.08% |
| 2021-12-31 | $408.15 Million | +36.84% |
| 2020-12-31 | $298.27 Million | +178.72% |
| 2019-12-31 | $107.01 Million | +109.43% |
| 2018-12-31 | $51.10 Million | +1237.99% |
| 2017-12-31 | $3.82 Million | -- |
About Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a po… Read more